These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1379065)

  • 1. Detection of hydatidiform mole in maternal serum screening programmes for Down's syndrome.
    Cuckle HS; Densem JW; Wald NJ
    Br J Obstet Gynaecol; 1992 Jun; 99(6):495-7. PubMed ID: 1379065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Stone RB
    Br J Obstet Gynaecol; 1992 Jan; 99(1):51-3. PubMed ID: 1372176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome.
    Wald N; Cuckle H; Wu TS; George L
    Br J Obstet Gynaecol; 1991 Sep; 98(9):905-8. PubMed ID: 1716981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-marker serum screening for Down's syndrome.
    Wald NJ; Densem JW; Smith D; Klee GG
    Prenat Diagn; 1994 Aug; 14(8):707-16. PubMed ID: 7527537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of free beta-hCG in antenatal screening for Down's syndrome.
    Wald N; Densem J; Stone R; Cheng R
    Br J Obstet Gynaecol; 1993 Jun; 100(6):550-7. PubMed ID: 7687460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group.
    Wald NJ; George L; Smith D; Densem JW; Petterson K
    Br J Obstet Gynaecol; 1996 May; 103(5):407-12. PubMed ID: 8624312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
    Wald NJ; Watt HC
    Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight.
    Wald NJ; Cuckle HS; Densem JW; Kennard A; Smith D
    Br J Obstet Gynaecol; 1992 Feb; 99(2):144-9. PubMed ID: 1372820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of allowing for ethnic group in prenatal screening for Down's syndrome.
    Watt HC; Wald NJ; Smith D; Kennard A; Densem J
    Prenat Diagn; 1996 Aug; 16(8):691-8. PubMed ID: 8878277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
    Extermann P; Bischof P; Marguerat P; Mermillod B
    Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gravidity on maternal serum markers for Down's syndrome.
    Barkai G; Goldman B; Ries L; Chaki R; Cuckle H
    Prenat Diagn; 1996 Apr; 16(4):319-22. PubMed ID: 8734805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taking account of vaginal bleeding in screening for Down's syndrome.
    Cuckle H; van Oudgaarden ED; Mason G; Holding S
    Br J Obstet Gynaecol; 1994 Nov; 101(11):948-53. PubMed ID: 7528053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of maternal serum alpha-fetoprotein and free beta human chorionic gonadotrophin in the first trimester: implications for Down's syndrome screening.
    Berry E; Aitken DA; Crossley JA; Macri JN; Connor JM
    Prenat Diagn; 1995 Jun; 15(6):555-65. PubMed ID: 7544898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second trimester serum tests for Down's Syndrome screening.
    Alldred SK; Deeks JJ; Guo B; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2012 Jun; 2012(6):CD009925. PubMed ID: 22696388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening.
    Wald NJ; White N; Morris JK; Huttly WJ; Canick JA
    Br J Obstet Gynaecol; 1999 Dec; 106(12):1304-6. PubMed ID: 10609726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ; Densem JW; George L; Muttukrishna S; Knight PG
    Prenat Diagn; 1996 Feb; 16(2):143-53. PubMed ID: 8650125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.